astria therapeutics glp-1 receptor agonist weight management diabetes treatments New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within Agonists GLP-1 Receptor Agonists Linked to

Einarson TR, Acs A, Ludwig C, Panton UH

[DOI] [PMC free article] [PubMed] [Google Scholar] 45.Kokkorakis M., Chakhtoura M., Rhayem C., Al Rifai J., Ghezzawi M., Valenzuela-Vallejo L., Mantzoros C.S

Trulicity is a once-weekly injection thats approved by the Food and Drug Administration (FDA) to control blood sugar in people 10 and older with Type 2 diabetes and to reduce the risk of heart attack, stroke, and cardiovascular death in adults with both Type 2 diabetes and cardiovascular disease (or multiple risk factors)

Together, these findings necessitate further investigations to ascertain whether coordinated inhibition of NMDA receptors in GLP-1 receptor neurons modulates neuronal activity beyond canonical feeding regions, such as the mesolimbic dopaminergic reward pathway

Lancet 330(8571):13001304 [Google Scholar] Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B et al (2020) Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5